Key Points
- Insider sale: Director Caryn Parlavecchio sold 6,600 shares on Jan. 16 at an average of $44.48 for $293,568, trimming her stake by 4.25% to 148,864 shares (valued at about $6.62M).
- Stock & financials: SRRK opened at $46.05 (trading up ~2.9%), has a market cap of $4.7B, a one‑year range of $22.71–$48.28 and a negative P/E of -14.62.
- Analysts & ownership: The consensus rating is "Buy" with a $50.14 target and heavy institutional ownership (91.08%), though the company recently missed quarterly EPS (‑$0.90) and is forecast to report about -2.42 EPS for the fiscal year.
Scholar Rock Holding Corporation (NASDAQ:SRRK - Get Free Report) insider Jing Marantz sold 5,798 shares of the company's stock in a transaction dated Friday, January 16th. The stock was sold at an average price of $44.48, for a total transaction of $257,895.04. Following the completion of the transaction, the insider owned 95,687 shares of the company's stock, valued at approximately $4,256,157.76. This trade represents a 5.71% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.
Scholar Rock Price Performance
NASDAQ:SRRK opened at $46.05 on Thursday. The stock has a market capitalization of $4.70 billion, a PE ratio of -14.62 and a beta of 0.63. Scholar Rock Holding Corporation has a 52 week low of $22.71 and a 52 week high of $48.28. The company has a quick ratio of 6.30, a current ratio of 6.30 and a debt-to-equity ratio of 0.41. The stock's 50-day moving average price is $43.23 and its 200-day moving average price is $37.16.
Scholar Rock (NASDAQ:SRRK - Get Free Report) last issued its quarterly earnings results on Friday, November 14th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.88) by ($0.02). During the same period in the prior year, the firm posted ($0.66) earnings per share. As a group, equities analysts expect that Scholar Rock Holding Corporation will post -2.42 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
A number of equities analysts have weighed in on the stock. Piper Sandler reduced their price objective on shares of Scholar Rock from $52.00 to $51.00 and set an "overweight" rating for the company in a research report on Wednesday, September 24th. Bank of America initiated coverage on shares of Scholar Rock in a research note on Thursday, October 9th. They issued a "buy" rating and a $53.00 price target on the stock. JPMorgan Chase & Co. boosted their price objective on Scholar Rock from $46.00 to $47.00 and gave the stock an "overweight" rating in a research note on Tuesday, November 18th. Wolfe Research began coverage on Scholar Rock in a research report on Tuesday, November 18th. They issued an "outperform" rating and a $42.00 target price on the stock. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Scholar Rock in a research note on Wednesday, October 8th. Four analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Buy" and an average target price of $50.14.
Get Our Latest Stock Report on Scholar Rock
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently made changes to their positions in the stock. Ramirez Asset Management Inc. purchased a new stake in shares of Scholar Rock in the third quarter valued at approximately $37,000. Penserra Capital Management LLC acquired a new position in Scholar Rock during the third quarter worth $56,000. Strs Ohio purchased a new stake in Scholar Rock in the 1st quarter valued at $77,000. Bessemer Group Inc. increased its stake in shares of Scholar Rock by 970.0% in the 3rd quarter. Bessemer Group Inc. now owns 2,322 shares of the company's stock worth $86,000 after acquiring an additional 2,105 shares during the last quarter. Finally, Elevation Point Wealth Partners LLC purchased a new position in shares of Scholar Rock during the 2nd quarter worth $94,000. 91.08% of the stock is currently owned by institutional investors and hedge funds.
Scholar Rock Company Profile
(
Get Free Report)
Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company's research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock's approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.
The company's lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
